<DOC>
	<DOCNO>NCT00079183</DOCNO>
	<brief_summary>This phase II trial study side effect well sirolimus work secondary therapy treat patient chronic graft-versus-host disease ( GVHD ) respond prior treatment . Sirolimus may effective treatment chronic GVHD</brief_summary>
	<brief_title>Sirolimus Secondary Therapy Treating Patients With Chronic Graft-Versus-Host Disease That Did Not Respond To Prior Treatment</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess safety sirolimus administer dose provide steady-state , whole blood trough level 5-10 ng/mL patient chronic GVHD . II . To determine whether administration sirolimus provide benefit patient chronic GVHD respond adequately previous systemic treatment . OUTLINE : Patients receive sirolimus orally ( PO ) daily ( QD ) . Patients continue receive prednisone cyclosporine tacrolimus discretion manage physician . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Biopsyconfirmed diagnosis clinical extensive chronic GVHD inadequate response previous treatment secondary systemic therapy indicate Clinical progression sign symptom chronic GVHD previously involve organ , Development sign symptom chronic GVHD previously uninvolved organ , Absence improvement 3 month primary treatment , Continued need treatment prednisone dose &gt; = 1.0 mg/kg/day 2 month , without qualification type donor , graft condition regimen Patient guardian able willing provide inform consent Stated willingness use contraception woman childbearing potential ( Food Drug Administration [ FDA ] requirement ) Stated willingness patient comply study procedure report requirement Stated willingness physician involve management chronic GVHD ( `` manage physician , '' ) comply study procedure report requirement Fungal viral infection radiographic evidence improvement continue appropriate antimicrobial therapy Cytomegalovirus ( CMV ) antigenemia unresponsive antiviral therapy Active disseminate varicella zoster virus ( VZV ) infection persistent noncrusted lesion Inability tolerate oral medication Absolute neutrophil count ( ANC ) &lt; 1500/uL Platelet count &lt; 50,000/uL Persistent recurrent malignancy , include histopathologic evidence myeloma lymphoma ; patient breakpoint cluster regionabelson ( bcr/abl ) detect polymerase chain reaction ( PCR ) assay evidence persistent chronic myeloid leukemia may enrol Pregnancy Known history hypersensitivity sirolimus</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>